Dengue Vaccine Market: By Product Type, DENVax, TetraVax-DV, Others), By Vaccine Type, By End User ) and Geography

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Dengue Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (CYD-TDV (Dengvaxia), DENVax, TetraVax-DV, Others), By Vaccine Type (Live Attenuated Vaccine, Killed Vaccine, Others), By End User (Hospitals, Clinics, Government Institutes, Non-Governmental Organizations (NGOs)) and Region

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Dengue Vaccine Market size was valued at US$ 472.6 million in 2023 and is poised to grow at a significant CAGR of 12.8% from 2024-2030. The market describes the area of the pharmaceutical industry devoted to the creation, manufacturing, and distribution of vaccinations intended to fend against dengue fever, a virus spread by mosquitoes. Numerous parties are involved in this market, including consumers, healthcare professionals, regulatory agencies, and makers of vaccines. As per the World Health Organization, the frequency of dengue has become significant over ongoing many years. A larger part of the cases are asymptomatic, gentle, or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue diseases each year (95% valid span 284-528 million), of which 96 million show clinically.  

summary download arrow Download Free Sample

Global Dengue Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.8%

Largest Market

Asia Pacific

Fastest Growing Market

North America

Dengue Vaccine Market Dynamics

Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegypti mosquito. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programmes to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.

Global Dengue Vaccine Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market CAGR

12.8%

By Product Type

  • CYD-TDV (Dengvaxia)
  • DENVax
  • TetraVax-DV
  • Others

By Vaccine Type

  • Live Attenuated Vaccine
  • Killed Vaccine
  • Others

By End Users

  • Hospitals
  • Clinics
  • Government Institutes
  • Non-Governmental Organization (NGOs)

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacifc
  • MIddle East and Africa

Key Features of the Report

  • The dengue vaccine market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The Dengue vaccine market size was valued at US$ 472.6 million in 2023

The Dengue vaccine market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

The Dengue vaccine market key players Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt. Ltd, Panacea Biotec Limited, Sanofi Pasteur Limited, GeneOne Life Science, Sun Pharmaceutical Industries Ltd.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Dengue Vaccine Market Introduction
2.1. Global Dengue Vaccine Market Taxonomy
2.2. Global Dengue Vaccine Market Definitions
2.2.1. By Product Type
2.2.2. By Vaccine Type
2.2.3. By End User
2.2.4. By Region
3. Global Dengue Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dengue Vaccine Market Dynamic Factors - Impact Analysis
3.6. Global Dengue Vaccine Market Competition Landscape
4. Global Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Dengue Vaccine Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
5.1. CYD-TDV (Dengvaxia)
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. DENVax
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. TetraVax-DV
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Dengue Vaccine Market, By Vaccine Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
6.1. Live Attenuated Vaccine
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Killed Vaccine
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Dengue Vaccine Market Forecast, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
7.1. Hospitals
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Clinics
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Government Institutes
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Non-Governmental Organizations (NGOs)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Dengue Vaccine Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Application, By End User, and Region, 2024 - 2030
9. North America Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. CYD-TDV (Dengvaxia)
9.1.2. DENVax
9.1.3. TetraVax-DV
9.1.4. Others
9.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Live Attenuated Vaccine
9.2.2. Killed Vaccine
9.2.3. Others
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Government Institutes
9.3.4. Non-Governmental Organizations (NGOs)
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030
9.6. North America Dengue Vaccine Market Dynamics Trends
10. Europe Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. CYD-TDV (Dengvaxia)
10.1.2. DENVax
10.1.3. TetraVax-DV
10.1.4. Others
10.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Live Attenuated Vaccine
10.2.2. Killed Vaccine
10.2.3. Others
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Government Institutes
10.3.4. Non-Governmental Organizations (NGOs)
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Benelux
10.4.8. Rest of Europe
10.5. Europe Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030
10.6. Europe Dengue Vaccine Market Dynamics Trends
11. Asia-Pacific Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
11.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. CYD-TDV (Dengvaxia)
11.1.2. DENVax
11.1.3. TetraVax-DV
11.1.4. Others
11.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Live Attenuated Vaccine
11.2.2. Killed Vaccine
11.2.3. Others
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Government Institutes
11.3.4. Non-Governmental Organizations (NGOs)
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030
11.6. Asia-Pacific Dengue Vaccine Market Dynamics Trends
12. Latin America Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
12.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. CYD-TDV (Dengvaxia)
12.1.2. DENVax
12.1.3. TetraVax-DV
12.1.4. Others
12.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Live Attenuated Vaccine
12.2.2. Killed Vaccine
12.2.3. Others
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Government Institutes
12.3.4. Non-Governmental Organizations (NGOs)
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030
12.6. Latin America Dengue Vaccine Market Dynamics Trends
13. Middle East and Africa Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
13.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. CYD-TDV (Dengvaxia)
13.1.2. DENVax
13.1.3. TetraVax-DV
13.1.4. Others
13.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Live Attenuated Vaccine
13.2.2. Killed Vaccine
13.2.3. Others
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Government Institutes
13.3.4. Non-Governmental Organizations (NGOs)
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030
13.6. MEA Dengue Vaccine Market Dynamics Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Takeda Pharmaceutical Company Limited
14.2.2. Serum Institute of India Pvt. Ltd
14.2.3. Panacea Biotec Limited
14.2.4. Sanofi Pasteur Limited
14.2.5. GeneOne Life Science
14.2.6. Sun Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

Key Market Players

  • Takeda Pharmaceutical Company Limited
  • Serum Institute of India Pvt. Ltd
  • Panacea Biotec Limited
  • Sanofi Pasteur Limited
  • GeneOne Life Science
  • Sun Pharmaceutical Industries Ltd.

Related Industry Reports

Egypt Diabetes Devices Market

Lithuania Surgical Equipment Market

Antimicrobials Market

Cancer Therapy Market